WO2004083387A3 - Anticorps anti-gangliosides et procedes d'utilisation correspondants - Google Patents

Anticorps anti-gangliosides et procedes d'utilisation correspondants Download PDF

Info

Publication number
WO2004083387A3
WO2004083387A3 PCT/US2004/007524 US2004007524W WO2004083387A3 WO 2004083387 A3 WO2004083387 A3 WO 2004083387A3 US 2004007524 W US2004007524 W US 2004007524W WO 2004083387 A3 WO2004083387 A3 WO 2004083387A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies
ganglioside
tumor cell
cell
Prior art date
Application number
PCT/US2004/007524
Other languages
English (en)
Other versions
WO2004083387A2 (fr
Inventor
Gary R Fanger
Original Assignee
Corixa Corp
Gary R Fanger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Gary R Fanger filed Critical Corixa Corp
Publication of WO2004083387A2 publication Critical patent/WO2004083387A2/fr
Publication of WO2004083387A3 publication Critical patent/WO2004083387A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à des procédés pour inhiber l'induction de l'apoptose des lymphocytes T par une cellule tumorale. Ces procédé peuvent servir notamment à bloquer l'apoptose des lymphocytes T induite par une cellule tumorale produisant la surexpression d'un ganglioside, tel qu'un monosialo-GM2. Ces procédés peuvent être utiles dans le traitement du cancer. Ces procédés consistent à mettre le ganglioside se trouvant sur la cellule tumorale en contact avec un anticorps ou un fragment de fixation d'antigène de cet anticorps, qui se lie spécifiquement au ganglioside. Ces anticorps peuvent être par exemple des anticorps de hamster, des anticorps de hamster/humains chimériques ou des anticorps humanisés.
PCT/US2004/007524 2003-03-13 2004-03-11 Anticorps anti-gangliosides et procedes d'utilisation correspondants WO2004083387A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45427003P 2003-03-13 2003-03-13
US60/454,270 2003-03-13

Publications (2)

Publication Number Publication Date
WO2004083387A2 WO2004083387A2 (fr) 2004-09-30
WO2004083387A3 true WO2004083387A3 (fr) 2004-11-25

Family

ID=33029868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007524 WO2004083387A2 (fr) 2003-03-13 2004-03-11 Anticorps anti-gangliosides et procedes d'utilisation correspondants

Country Status (1)

Country Link
WO (1) WO2004083387A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2581523T3 (es) 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003049704A2 (fr) * 2001-12-11 2003-06-19 University Of Massachusetts Anticorps utiles dans le traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003049704A2 (fr) * 2001-12-11 2003-06-19 University Of Massachusetts Anticorps utiles dans le traitement du cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOON D.S.B. ET AL.: "Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lypmhokine-activated killer cells", INT. J. CANCER., vol. 43, 1989, pages 857 - 862 *
ZHOU J. ET AL.: "Gangliosides enhance apoptosis of thymocytes", CELLULAR IMMUNOLOGY, vol. 183, 1998, pages 90 - 98 *

Also Published As

Publication number Publication date
WO2004083387A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2006066078A3 (fr) Anticorps specifiques de fc$g(g)riib et leurs procedes d'utilisation
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
WO2007084181A3 (fr) Molécules d'anticorps fv à chaîne unique bispécifiques et procédés d'utilisation de celles-ci
WO2005012493A3 (fr) Anticorps anti-cd19
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2008140493A3 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
WO2006084075A3 (fr) Modulateurs adam-9
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
WO2007109376A3 (fr) Thérapeutique anticorps antigène de cellules anti-tumorales
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2006099141A3 (fr) Anticorps diriges contre la mesotheline
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
WO2008108986A3 (fr) Procédés et compositions permettant de traiter des maladies tumorales
WO2006130773A3 (fr) Methodes de traitement des tumeurs du cerveau a l'aide d'anticorps
WO2009071696A3 (fr) Molécules d'anticorps humanisés spécifiques pour il-31
WO2012106556A3 (fr) Méthodes et compositions associées à l'inhibition d'igf-1r
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
WO2005090406A3 (fr) Compositions polypeptidiques pour inhiber l'angiogenese et la croissance tumorale
WO2019060750A3 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
ZA202008095B (en) Humanized antibodies against psma
WO2005047328A3 (fr) Anticorps diriges contre l'inhibiteur de la protease des leucocytes secreteurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 69 1 EPC

122 Ep: pct application non-entry in european phase